Overlapping Therapy with High-Dose Tamoxifen and CYP2D6 Inhibitors Modifies Medication Adherence in Breast Cancer Patients

被引：0
|
作者：
Markward, N. J.
Tinnirello, J.
Khalid, M.
Frueh, F. W.
Milayna, S.
Aubert, R. E.
Epstein, R. S.
机构：
[1] Medco Hlth Solut Inc, Bethesda, MD USA
[2] Medco Hlth Solut Inc, Franklin Lakes, NJ USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P4-02-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-15
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Imamura, Chiyo K.
    Tanigawara, Yusuke
    Hosono, Naoya
    Kubo, Michiaki
    Sasa, Mitsunori
    Nakamura, Yusuke
    Zembutsu, Hitoshi
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (01) : 137 - 145
  • [22] Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen Reply
    Dezentje, Vincent O.
    van Blijderveen, Nico J. C.
    Gelderblom, Hans
    Putter, Hein
    van Herk-Sukel, Myrthe P. P.
    Casparie, Mariel K.
    Egberts, Antoine C. G.
    Nortier, Johan W. R.
    Guchelaar, Henk-Jan
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : E586 - E586
  • [23] Impact of the CYP2D6 phenotype on the outcome of breast cancer patients treated with tamoxifen
    Dorado, Pedro
    Penas-Lledo, Eva
    LLerena, Adrian
    PHARMACOGENOMICS, 2013, 14 (06) : 606 - 606
  • [24] The Impact of CYP2D6*4 on the Survival of Tamoxifen Treated Breast Cancer Patients
    Al Matrafi, Abdullah
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1345 - 1346
  • [25] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
    He, Wei
    Grassmann, Felix
    Eriksson, Mikael
    Eliasson, Erik
    Margolin, Sara
    Thoren, Linda
    Hall, Per
    Czene, Kamila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 548 - +
  • [26] Impact of CYP2D6 Genotype and Side-Effects on Adherence Rates to Tamoxifen in Premenopausal Breast Cancer Patients
    Hubalek, M.
    Oberguggenberger, A.
    Meraner, V.
    Beer, B.
    Giesinger, J.
    Oberacher, H.
    Sperner-Unterweger, B.
    Marth, C.
    CANCER RESEARCH, 2010, 70
  • [27] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [28] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [29] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [30] CYP2D6*3, *4, *6 GENOTYPES AND ENDOMETRIAL THICKNESS IN PATIENTS WITH BREAST CANCER DURING TAMOXIFEN THERAPY
    Goryainova, A. Yu
    Usman, N. Yu
    Rubanovich, A., V
    Borinskaya, S. A.
    Meshcheryakov, A. A.
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2023, (05): : 18 - 25
12345